Published in Clin Diagn Lab Immunol on September 01, 1997
The MHV68 M2 protein drives IL-10 dependent B cell proliferation and differentiation. PLoS Pathog (2008) 1.11
EBV Zta protein induces the expression of interleukin-13, promoting the proliferation of EBV-infected B cells and lymphoblastoid cell lines. Blood (2009) 0.97
Tyrosine 129 of the murine gammaherpesvirus M2 protein is critical for M2 function in vivo. PLoS One (2014) 0.78
Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell (1991) 7.40
Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science (1990) 7.18
Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol (1990) 4.24
The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol (1990) 4.03
Epstein-Barr virus persistence and virus-associated tumours. Lancet (1994) 2.60
Properties and functions of interleukin-10. Adv Immunol (1994) 2.46
Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res (1981) 2.39
Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation (1985) 2.34
Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation (1990) 2.13
Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1: pathological significance. Ann N Y Acad Sci (1992) 2.06
Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10. J Exp Med (1993) 2.00
Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders. Lancet (1991) 1.95
The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation (1988) 1.72
Epstein Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft. Lancet (1980) 1.60
Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. J Exp Med (1995) 1.42
Expression of Epstein-Barr virus-encoded growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients. Int J Cancer (1991) 1.36
Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine (Baltimore) (1991) 1.25
Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood (1996) 1.21
Interleukin-10 inhibits apoptotic cell death in infectious mononucleosis T cells. J Clin Invest (1994) 1.11
Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection, and rejection episodes in renal transplant recipients. Transplantation (1995) 1.04
Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation. Transplantation (1994) 1.03
EBV-activation of human B-lymphocytes. Curr Top Microbiol Immunol (1986) 0.98
The Epstein-Barr virus encoded cytokine viral interleukin-10 enhances transformation of human B lymphocytes. Oncogene (1995) 0.92
Immunocytochemical detection of Epstein-Barr virus antigens in peripheral B lymphocytes after renal transplantation. Transplantation (1995) 0.91
Cellular and molecular bases of B-cell clonal expansions. Clin Exp Rheumatol (1996) 0.87
Adhesion molecules and transplantation. Ann Surg (1994) 0.85
Interferon-alpha affects the immune response in post-transplant lymphoproliferative disorder. Am J Respir Crit Care Med (1996) 0.82
Soluble Fc epsilon RII/CD23 in patients with autoimmune diseases and Epstein-Barr virus-related disorders: analysis by ELISA for soluble Fc epsilon RII/CD23. Immunomethods (1994) 0.78
CD23 and the Epstein-Barr virus. Res Immunol (1992) 0.77
Soluble CD23 as a sensitive marker for Epstein-Barr virus-related disorders after liver transplantation. Transplantation (1993) 0.77
ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents. EMBO J (1995) 4.28
Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature (1982) 3.26
Antiviral effects of recombinant tumour necrosis factor in vitro. Nature (1986) 3.25
The immunobiology of zinc. Immunol Today (1997) 2.93
Stimulation of c-Jun activity by CBP: c-Jun residues Ser63/73 are required for CBP induced stimulation in vivo and CBP binding in vitro. Oncogene (1995) 2.64
High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis (1998) 2.48
Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology (2000) 2.46
EndoResect study: endoscopic full-thickness resection of gastric subepithelial tumors. Endoscopy (2012) 2.44
Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus. J Exp Med (1974) 2.40
Splenic suppressor macrophages induced in mice by injection of Corynebacterium parvum. J Immunol (1975) 2.13
Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol (2004) 2.07
Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant (2008) 2.07
Interferon-gamma production by Listeria monocytogenes-specific T cells active in cellular antibacterial immunity. Eur J Immunol (1983) 2.06
[Antireflux operations: indications and techniques]. Chirurg (2013) 1.97
Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet (1990) 1.80
Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst (1996) 1.79
Prospective age-matching in elderly kidney transplant recipients--a 5-year analysis of the Eurotransplant Senior Program. Am J Transplant (2007) 1.72
Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost (2009) 1.70
Low ferritin levels indicate the need for iron supplementation: strategy to minimize iron-depletion in regular blood donors. Transfus Med (2000) 1.67
Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction. J Clin Microbiol (1992) 1.66
Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice. J Immunol (1975) 1.62
Failure to detect human cytomegalovirus DNA in peripheral blood leukocytes of healthy blood donors by the polymerase chain reaction. Transfusion (1992) 1.60
Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol (1995) 1.58
Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand (1988) 1.57
Interferon treatment inhibits onset of herpes simplex virus immediate-early transcription. Virology (1988) 1.55
Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol (1996) 1.55
Two functionally distinct anti-tumor effector cells isolated from primary murine sarcoma virus-induced tumors. J Immunol (1976) 1.53
Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol (1992) 1.50
Altered cytokine production in the elderly. Mech Ageing Dev (1998) 1.47
Polyclonal immunoglobulin secretion by human B lymphocytes exposed to Epstein-Barr virus in vitro. J Immunol (1979) 1.46
Plasma endothelin-1 in patients with left-to-right shunt. Am Heart J (1995) 1.45
Production of immune interferon by murine T-cell clones from long-term cultures. Nature (1981) 1.45
Sox genes and cancer. Cytogenet Genome Res (2004) 1.42
IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer (2001) 1.42
Production of cytokines in acute schizophrenic psychosis. Biol Psychiatry (1996) 1.41
[An interuniversity comparison of the supervision of doctoral candidates--should the promotion procedures be changed?]. Dtsch Med Wochenschr (2000) 1.40
Transposition of the great arteries with straddling tricuspid valve. Report of two rare cases with acquired subaortic stenosis after main pulmonary artery banding. J Thorac Cardiovasc Surg (1989) 1.39
[The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation]. Dtsch Med Wochenschr (1997) 1.39
Coincidence of neonatal alloimmune thrombocytopenia and maternal anti-D immunization: case report. Br J Haematol (1998) 1.37
Ex vivo induction of cytokine mRNA expression in human blood samples. J Immunol Methods (2001) 1.37
The detection of human cytomegalovirus immediate early antigen in peripheral blood leucocytes. J Immunol Methods (1991) 1.35
The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J Immunol Methods (2000) 1.34
Kinetics of the Zn 2+ - stimulation of human peripheral lmphocytes in vitro. Proc Soc Exp Biol Med (1971) 1.34
Patent ductus arteriosus in very low birthweight infants: complications of pharmacological and surgical treatment. J Perinat Med (2001) 1.29
Identification of herpes simplex virus type 1 (HSV-1) glycoprotein gC as the immunodominant antigen for HSV-1-specific memory cytotoxic T lymphocytes. J Immunol (1985) 1.28
Genetic variability of herpes simplex virus: development of a pathogenic variant during passaging of a nonpathogenic herpes simplex virus type 1 virus strain in mouse brain. J Virol (1983) 1.27
Antiviral activity of tumour necrosis factor. Synergism with interferons and induction of oligo-2',5'-adenylate synthetase. J Gen Virol (1988) 1.26
Experimental infection of inbred mice with herpes simplex virus type 1. I. Investigation of humoral and cellular immunity and of interferon induction. J Gen Virol (1981) 1.25
Failure to detect antiviral activity in serum and plasma of healthy individuals displaying high activity in ELISA for IFN-alpha and IFN-beta. J Interferon Cytokine Res (1999) 1.24
Replication of herpes simplex virus in human T lymphocytes: characterization of the viral target cell. J Immunol (1984) 1.24
In vitro mitogenic stimulation of murine spleen cells by herpes simplex virus. J Immunol (1978) 1.24
Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J (1997) 1.23
Zinc-altered immune function and cytokine production. J Nutr (2000) 1.22
The effects of general anesthesia on human peripheral immune cell distribution and cytokine production. Clin Immunol Immunopathol (1997) 1.21
Continuous cytomegalovirus seroconversion in a large group of healthy blood donors. Vox Sang (2004) 1.20
Prostaglandin synthesis in spleen cell cultures of mice injected with Corynebacterium parvum. Cell Immunol (1978) 1.20
Development, standardization, and evaluation of NOTES cholecystectomy using a transsigmoid approach in the porcine model: an acute feasibility study. Endoscopy (2007) 1.19
Human cytomegalovirus replicates in primary human bone marrow cells. J Gen Virol (1986) 1.18
Cytokine production and serum proteins in depression. Scand J Immunol (1995) 1.18
Experimental infection of inbred mice with herpes simplex virus. V. Investigations with a virus strain non-lethal after peripheral infection. J Gen Virol (1982) 1.18
Rapid HLA-DRB1 genotyping by nested PCR amplification. Tissue Antigens (1992) 1.16
Pokeweed mitogen-, concanavalin A-, and phytohemagglutinin-induced development of cytotoxic effector lymphocytes. An evaluation of the mechanisms of T cell-mediated cytotoxicity. J Exp Med (1973) 1.16
The role of interferon in the resistance of C57BL/6 mice to various doses of herpes simplex virus type 1. J Infect Dis (1982) 1.16
Inhibition of the mixed lymphocyte culture by peritoneal exudate cells. Cell Immunol (1976) 1.15
Stimulation of chicken lymphocytes in a serum-free medium. Cell Immunol (1972) 1.15
Mycoplasma contamination in human tumor cell lines: effect on interferon induction and susceptibility to natural killing. J Immunol (1981) 1.13
The DNA-binding protein pUL57 of human cytomegalovirus is a major target antigen for the immunoglobulin M antibody response during acute infection. J Clin Microbiol (1995) 1.12
Novel PCR assay for determining the genetic sex of mice. Sex Dev (2013) 1.11
Quantification of murine IFN-gamma mRNA and protein expression: impact of real-time kinetic RT-PCR using SYBR green I dye. Scand J Immunol (2001) 1.09
A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation (2001) 1.09
Dysregulation between TH1 and TH2 T cell subpopulations in the elderly. Mech Ageing Dev (1996) 1.08
A reappraisal of the effector cells mediating mitogen induced cellular cytotoxicity. Cell Immunol (1975) 1.08
Clonal analysis of human T cell activation by the Mycoplasma arthritidis mitogen (MAS). Eur J Immunol (1988) 1.08
An X-linked locus influences the amount of circulating interferon induced in the mouse by herpes simplex virus type 1. J Gen Virol (1982) 1.08
A novel polymorphism in the 5' promoter region of the human interleukin-4 receptor alpha-chain gene is associated with decreased soluble interleukin-4 receptor protein levels. Immunogenetics (2001) 1.07
Cytomegalovirus transcripts in peripheral blood leukocytes of actively infected transplant patients detected by reverse transcription-polymerase chain reaction. J Infect Dis (1993) 1.07
Inflammatory markers in major depression and melancholia. J Affect Disord (2001) 1.07
Transgastric in vivo histology in the peritoneal cavity using miniprobe-based confocal fluorescence microscopy in an acute porcine model. Endoscopy (2007) 1.06
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol (2008) 1.06
Inhibition of in vitro lymphoproliferative responses to tumor-associated antigens by suppressor cells from rats bearing progressively growing Gross leukemia virus-induced tumors. Int J Cancer (1975) 1.05
Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol Psychiatry (2001) 1.05
Normalized quantification by real-time PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disorders. J Clin Microbiol (2001) 1.05
The "ELITE" model: construct validation of a new training system for natural orifice transluminal endoscopic surgery (NOTES). Endoscopy (2009) 1.04
Kinetics and organ distribution of allogeneic natural killer lymphocytes transfused into patients suffering from renal cell carcinoma. Stem Cells Dev (2004) 1.04
Protection against herpes simplex virus infection in mice by Corynebacterium parvum. Infect Immun (1977) 1.04
Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection, and rejection episodes in renal transplant recipients. Transplantation (1995) 1.04
A promoter polymorphism in the CD14 gene is associated with elevated levels of soluble CD14 but not with IgE or atopic diseases. Allergy (2004) 1.04
Stimulation of human peripheral lymphocytes by Zn2+ in vitro. Exp Cell Res (1970) 1.04
Evaluation of a novel mononuclear cell isolation procedure for serological HLA typing. Clin Diagn Lab Immunol (1998) 1.03
Recent progress in the tumor necrosis factor-alpha field. Int Arch Allergy Immunol (1996) 1.03
Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma. Br J Cancer (1999) 1.03
A whole-blood technique for testing production of human interferon by leukocytes. J Immunol Methods (1982) 1.03
Human peripheral null lymphocytes. II. Producers of type-1 interferon upon stimulation with tumor cells, Herpes simplex virus and Corynebacterium parvum. Eur J Immunol (1980) 1.02